^
Association details:
| Biomarker: | ANGPT2 elevation |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Baseline angiopoietin-2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma
Published date:
04/11/2020
Excerpt:
We identified patients with unresectable HCC who were treated with sorafenib or lenvatinib...Responder rate was 40% (2/5) in patients with high baseline ANG2 and FGF19 levels who received sorafenib.
DOI:
10.1002/jgh3.12339
